ArticleNeuro-oncology advances

TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma.

Alberto Picca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.